Most Read Articles
Stephen Padilla, 21 Nov 2018
Use of triple therapy consisting of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA) and inhaled corticosteroid (ICS) leads to a reduced rate of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) and better lung function and health-related quality of life compared with dual therapy (ICS and LABA or LAMA and LABA) or LAMA monotherapy, according to the results of a meta-analysis.

Aspirin use beneficial to patients with AECOPD

08 Mar 2018

Aspirin use in patients with acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) is associated with lower rates of in-hospital mortality, reduced use of invasive mechanical ventilation and shorter hospital length-of-stay, a study suggests.

Researchers looked at 206,686 patients aged ≥40 years with hospitalization for AECOPD, which included 13,826 (7 percent) aspirin users. Compared with nonusers, aspirin users were older and more likely to have comorbidities (p<0.001).

In regression models, aspirin use was significantly associated with lower in-hospital mortality (adjusted odds ratio [OR], 0.60; 95 percent CI, 0.50–0.72; p<0.001) and lower rate of invasive mechanical ventilation use (adjusted OR, 0.64; 0.55–0.73; p<0.001).

No significant difference in the rate of noninvasive positive pressure ventilation use was observed between aspirin users and nonusers (adjusted OR, 1.05; 0.98–1.12; p=0.20).

Hospital length-of-stay was significantly shorter in aspirin users vs nonusers (median, 3 vs 4 days). Specifically, aspirin use was associated with a 7-percent decrease in length-of-stay (p<0.001).

The point estimates of the said associations did not change significantly in a sensitivity analysis excluding patients with history of coronary artery diseases, ischaemic stroke and/or heart failure.

Although causal inferences remain premature, the present data, along those from prior studies demonstrating the benefits of aspirin use in COPD patients, suggest that aspirin—a widely used and inexpensive medication—represents a potential therapeutic option in the management of COPD, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 21 Nov 2018
Use of triple therapy consisting of a long acting muscarinic antagonist (LAMA), long acting β agonist (LABA) and inhaled corticosteroid (ICS) leads to a reduced rate of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) and better lung function and health-related quality of life compared with dual therapy (ICS and LABA or LAMA and LABA) or LAMA monotherapy, according to the results of a meta-analysis.